“When health care becomes more expensive, people may be tempted to postpone doctor’s appointments or take their health entirely into their own hands,” said Karen Howard, CEO and executive director of ...

Egg Medical emphasizes a flexible, safety-first philosophy: Lead-Free, Responsibly. Modern interventional labs are not one-size-fits-all, and EggNest technology is engineered to support apron-optional ...

As Nobel laureates engage with China’s brain-health sector, Levitt and Moser’s choice to join the conversation brings the country’s emerging industry into the Nobel spotlight. It marks a milestone in ...

The Healthcare Financial Management Association (HFMA) is calling on financial leaders across sectors to sign a Declaration on Healthcare Affordability and Sustainability, which commits to an ...

Novartis announced today that the European Commission (EC) has approved Cosentyx ® (secukinumab) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to ...

Alignment Health Plan, an award-winning Medicare Advantage plan from Alignment Health, today announced it will expand into Nye County beginning Jan. 1, 2027, offering new Medicare Advantage plan ...

Eyonis Inc., a Median Technologies company developing artificial intelligence (AI) software for early cancer detection and diagnosis, will deliver two presentations at the 50th International ...

The FDA agreed that NDA (New Drug Application)-enabling studies, including in certain specific patient populations, can be conducted in parallel with the Phase 3 program, which the companies believe ...

VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd There are currently no FDA approved treatments for measles, leaving a major ...

Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with ...

SUN-627 demonstrated near complete inhibition of the TYK2 pathway, achieving greater than 90% reduction of key TYK2 pathway biomarkers for 24 hours with a once-daily dose, as well as a CNS-penetration ...

(Nasdaq: CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16 th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory ...